Milestone Achievement: First COPD Patient Dosed in Phase 1 Trial
We are pleased to share a historic milestone in regenerative medicine. On July 11, 2025, at Veritus Research in Melbourne, Australia, we administered the first dose of our Small Mobile Stem (SMS) cell therapy to a patient in our Phase 1 human clinical trial for Chronic Obstructive Pulmonary Disease (COPD).
This marks the first time our groundbreaking regenerative therapy has been delivered to a human patient—transitioning years of research into clinical reality.
About the Trial
- Title: A study to investigate Small Mobile Stem Cells (SMS cells) in participants aged 39–69 years with COPD
- Participants: 18 patients
- Objective: Evaluate safety and preliminary efficacy
- Delivery Method: Simple nebulizer for direct lung delivery
- Duration: Approximately 15 months
Our SMS cells are bio-manufactured at SMSbiotech and are designed to regenerate damaged lungs and other tissues. Preclinical studies have shown the potential to restore healthy lung function in animals in as little as 10 days.
Regulatory Approval
The trial is authorized by the Therapeutic Goods Administration (TGA), Australia’s regulatory body, comparable to the U.S. FDA.
A Message from Our President (maybe include photo)
“This is a profound moment for SMSbiotech and for millions living with COPD. We are optimistic about the potential of our therapy to fundamentally change the course of this disease.”
— Dr. Abdulkader Rahmo, President of SMSbiotech
This milestone strengthens our position in the global regenerative medicine market and supports our long-term strategy to deliver shareholder value through the development of innovative therapies. SMSbiotech will be increasing the dollar value of the stock price based on the crucial milestone.
We believe this achievement will generate heightened interest in SMSbiotech from both the scientific and investment communities.
We are also exploring applications for compassionate use once safety data becomes available, and evaluating potential indications in orthopedics based on very promising animal data in vitro studies.
